KRAS and digestive system neoplasm: Further, in the same team’s Phase I dose-escalation trial, the BN-CV301 vaccine, incorporating MUC1 and CEA, was shown to be safe and to elicit specific T-cell responses against these tumor antigens in most patients, with significant disease stabilization observed particularly in patients with KRAS-mutated gastrointestinal tumors undergoing anti-PD-L1 therapy, underscoring its potential in immunotherapy (176).